VG Life Sciences Inc. (VGLS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -20.34 Thousand | -25.56 Thousand | - | - | - | -45.71 Thousand |
| Net Income | -2.53 Million | 2.11 Million | -1.24 Million | -1.45 Million | -268.43 Thousand | -2.08 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 57.37 Thousand | 44.12 Thousand | 1.24 Million | 1.48 Million | 302.84 Thousand | 764.29 Thousand |
| Other non-cash items | 2.45 Million | -2.18 Million | - | -34.4 Thousand | -34.4 Thousand | 1.27 Million |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 20.34 Thousand | 25.56 Thousand | - | - | - | 41 Thousand |
| Debt repayment | -20.34 Thousand | -19.38 Thousand | - | - | - | -41 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | 6173.00 | - | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 57.37 Thousand | 44.12 Thousand | 1.24 Million | 1.48 Million | 302.84 Thousand | 764.29 Thousand |
| Cash at beginning of period | - | - | - | - | - | - |
| Cash at end of period | - | - | - | - | - | -4718.00 |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | - | - | - | -4718.00 |
| Free Cash Flow | -20.34 Thousand | -25.56 Thousand | - | - | - | -45.71 Thousand |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 2.42 Million | -2.53 Million | -2.5 Million | -3234.00 | -6453.00 | -16.02 Thousand |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 15.29 Thousand | 57.37 Thousand | 56.3 Thousand | 247.00 | 233.00 | 589.00 |
| Other non-cash items | -2.44 Million | 2.45 Million | 2.44 Million | 1287.00 | -2690.00 | 11.36 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 6189.00 | 20.34 Thousand | 5660.00 | 1700.00 | 8910.00 | 4073.00 |
| Debt repayment | -6189.00 | -20.34 Thousand | -5660.00 | -1700.00 | -8910.00 | -4073.00 |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 15.29 Thousand | 57.37 Thousand | 56.3 Thousand | 247.00 | 233.00 | 589.00 |
| Cash at beginning of period | - | - | - | - | - | - |
| Cash at end of period | - | - | - | - | - | - |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | - | - | - | - |
| Free Cash Flow | -6189.00 | -20.34 Thousand | -5660.00 | -1700.00 | -8910.00 | -4073.00 |
4886
TELDF
ACGI
0LQQ
DRCT
ULTJ